Siemens Healthineers AG issued the following announcement August 5.
The Food and Drug Administration (FDA) has cleared the SOMATOM On.site, a mobile head computed tomography (CT) scanner from Siemens Healthineers that enables a critically ill patient to receive CT head imaging in the intensive care unit (ICU) while remaining in bed. Performing a CT head examination at the patient’s bedside can eliminate costly transports to the radiology department, which involve high staffing requirements and potential patient risk. With the SOMATOM On.site, Siemens Healthineers enables reliable and consistent image quality at the point of care, allowing customers to transform care delivery.
"The SOMATOM On.site transforms the delivery of care for critically ill patients who require a CT head scan,” says Douglas Ryan, Vice President of Computed Tomography at Siemens Healthineers North America. “The system delivers reliable and consistent image quality demanded by healthcare professionals in the ICU, neurology, and radiology departments. Additionally, bedside imaging helps to reduce patient transports, thereby reducing the risk of infection while improving workforce efficiency.”
The SOMATOM On.site offers easy scan setup, fast workflow, and integrated patient support accessories, for convenient and consistent patient positioning in the scanner. An intelligent user interface concept, myExam Companion helps the radiologic technologist navigate the examination for consistent results. An integrated drive camera enables real-time viewing on the built-in Touch UI display for easy maneuvering by the technologist. The scanner’s unique telescopic gantry design allows the radiation source to move away from the patient during scanning, while the base and the front cover of the gantry remain stationary. The SOMATOM On.site system design – with the telescopic, self-shielded gantry and attachable front and back radiation shields – reduces scatter radiation compared to CT scanners without this design and provides radiation protection for neighboring patients and staff.
For further information on the SOMATOM On.site, please see
siemens-healthineers.us/somatom-onsite
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion.
Further information is available at www.siemens-healthineers.com.
Original source can be found here.
